Continuing pursuit for ideal systemic anticancer radiotherapeutics

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 2050-2065

  Cona, Marlein Miranda ^a   Wang, Huaijun ^a   Li, Junjie ^a   Feng, Yuanbo ^a   Chen, Feng ^a   De Witte, Peter ^a   Verbruggen, Alfons ^a   Ni, Yicheng ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anticancer agents; Cancer; Necrosis avid agent; Radioisotopes; Systemic targeted therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANGIOPEPTIN; EVANS BLUE; HEMATOPORPHYRIN; HYDROXYETHYLIDENE DIPHOSPHONATE RE 186; HYDROXYETHYLIDENE DIPHOSPHONATE RE 188; HYPERICIN; IBRITUMOMAB TIUXETAN; IODINE 131; LANREOTIDE RE 188; LEXIDRONAM SAMARIUM SM 153; LUTETIUM 177; METALLOPORPHYRIN; MONOCLONAL ANTIBODY; OCTREOTIDE; PASIREOTIDE; PEPTIDE; PHOSPHATE P 32; POTASSIUM IODIDE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STRONTIUM 89; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VAPREOTIDE RE 188; VASCULAR TARGETING AGENT; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER RADIOTHERAPY; DIFFERENTIATED THYROID CANCER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; HUMAN; INTERNALIZATION; NEUROBLASTOMA; NONHUMAN; PHEOCHROMOCYTOMA; PHOTODYNAMIC THERAPY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIOFREQUENCY ABLATION; RADIOIMMUNOTHERAPY; RADIOTHERAPY; SYSTEMIC METABOLIC RADIOISOTOPE THERAPY; SYSTEMIC TARGETED RADIOTHERAPY; THROMBOCYTHEMIA; THYROTOXICOSIS; TUMOR NECROSIS;

ANIMALS; HUMANS; NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 84867865246     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9758-6     Document Type: Article

References (175)

1. Garcia M, Jemal A, Ward EM, et al. (2007) Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society: 1.
2. Ni Y, Cresens E, Adriaens P, et al. (2002) Necrosis avid contrast agents: introducing nonporphyrin species. Acad Radiol 9(suppl 1):S98-S101
3. Ni Y, Cresens E, Adriaens P, et al. (2002) Exploring multifunctional features of necrosis avid contrast agents. Acad Radiol 9(suppl 2):S488-S490
4. Ni Y, Van de Putte M, de Witte P, et al. (2007) Targeted Radiotherapy. WO 2009/067767, International Patent. PCT-2008-000099.
5. Li J, Sun Z, Zhang J, Shao H, et al. (2011) A dual targeting anticancer approach: soil and seed principle. Radiology 260:799-807
6. The World Health Organization (2008) Are the numbers of cancer cases increasing or decreasing in the world? Available at: http://www.who.int/ features/qa/15/en/index.html (Accessed 16 January 2010).
7. Cancer research centre. Cancer Overview. www.cancer-research-center.com/ (Accessed 27 January 2011).
8. Venook AP and Selim S (2002) Metastatic Cancer. Everyones Guide to Cancer Therapy by Malin Dollinger, Ernest H. Rosenbaum, Margaret Tempero and Sean Mulvihill. Andrews McMeel. 4th edition, University of California San Francisco Comprehensive Cancer Centre.
9. Mosby's Medical Dictionary, 8th edition (2009) Elsevier. ISBN: 978-0-323-05290-0. http://medicaldictionary.thefreedictionary.com/ environmental+carcinogen. (Accessed 16 March 2011)
10. International Agency for Research on Cancer (2007) The causes of cancer. In: Stewart BW, Kleihues P (eds) World cancer report. IARC, Lyon, pp 21-82
11. The World Health Organization (2010) Up to 40% of cancer cases could be prevented. Available at: http://www.euro.who.int/en/what-we-publish/information- for-the-media/sections/press-releases/2010/02/up-to-40-of-cancer-cases-could-be- prevented (Accessed 26 January 2011)
12. Ni Y, Mulier S, Miao Y, et al. (2005) A review of the general aspects of radiofrequency ablation. Abdom Imaging 30:381-400
13. Polsdorfer JR (2002) Surgical removal of tumor, the gale group Inc., Gale, Detroit, Gale Encyclopedia of Medicine. http://healthtools.aarp.org/ galecontent/tumor-removal/1 (Accessed 19 March 2011)
14. Frei E 3rd (1985) Curative cancer chemotherapy. Cancer Res 45(12 Pt 1):6523-6537
15. Wardman P (2007) Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 19(6):397-417
16. Carlsson J, Aronsson EF, Hietala SO, et al. (2003) Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66:107-117
17. Ni Y, Li J, Miranda-Cona M, et al. (2009) Exploitation of Necrosis Avidity: from Diagnostics to Theragnostics in Oncology. In: Proceedings of the Contrast Media Research 2009, Copenhagen, Denmark. (With the Elliott Lasser Award for the best scientific presentation, CMR 2009): pp 99-101
18. Murthy R, Nunez R, Szklaruk J, et al. (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25:S41-S55
19. Raoul JL, Guyader D, Bretagne JF (1994) Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intraarterial iodine-131-iodized oil versus medical support. J Nucl Med 35:1782-1787
20. Klingebiel T, Berthold F, Treuner J, et al. (1991) Metaiodobenzylguanidine (MIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol 19(2):84-88
21. Scholz T, Eisenhofer G, Pacak K, et al. (2007) Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92(4):1217-1225
22. Parmentier C (2003) Use and risks of phosphorus-32 in the treatment of polycythaemia vera. Eur J Nucl Med Mol Imaging 30(10):1413-1417
23. Ni B (2000) Treatment of the myeloproliferative disorders with 32P. Review Eur J Haematol 65(1):1-7
24. Lee CK, Aeppli DM, Unger J, et al. (1996) Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol 19(2):102-107
25. Sartor O (2004) Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol 6(Suppl 10):S3-S12
26. Liepe K, Runge R, Kotzerke J (2005) Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care 22(6):457-464
27. Amzel LM, Poljak RJ (1979) Three-dimensional structure of immunoglobulins. Annu Rev Biochem 48:961-997
28. Goto Y, Hamaguchi K (1979) The role of the intrachain disulfide bond in the conformation and stability of the constant fragment of the immunoglobulin light chain. J Biochem 86:1433-1441
29. Goni F, Frangione B (1983) Amino acid sequence of the Fv region of a human monoclonal IgM (protein WEA) with antibody activity against 3, 4-pyruvylated galactose in Klebsiella polysaccharides K30 and K3. Proc Natl Acad Sci USA 80:4837-4841
30. Heyman B (1996) Complement and Fc-receptors in regulation of the antibody response. Immunol Lett 54(2-3):195-199
31. Parham P (2009) The immune system (3 rd Edition) Garland Science, Taylor and Francis Group, LLC: G:2
32. Van Denderen J, Ten Hacken P, Berendes P, et al. (1993) Detection of tumor-specific antigens in philadelphia chromosome positive leukemias. Leuk Lymphoma 11(1):29-32
33. Linley AJ, Ahmad M, Rees RC (2011) Tumour-associated antigens: considerations for their use in tumour immunotherapy. Int J Hematol 93:263-273
34. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497
35. Spieker-Polet H, Periannan S, Pi-Chen Y, et al. (1995) Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci USA 92:9348-9352
36. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129
37. Weiner LM (1999) Monoclonal antibody therapy of cancer. Semin Oncol 26(5):43-51
38. Borghaei H, Schilder RJ (2004) Safety and efficacy of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 34(Suppl 1):4-9
39. 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 46(Suppl 1):128S-140S
40. Goldenberg DM, Griffiths GL (1992) Radioimmunotherapy of cancer: arming the missiles. J Nucl Med 33:1110-1112
41. Jain RK (1987) Transport of molecules across tumour vasculature. Cancer Metastasis Rev 6:559-593
42. Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54:11-29
43. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:448-449
44. Hoogenboom HR, Chames P (2000) Natural and designer binding sites made by phage display technology. Immunol Today 21(8):371-378
45. Feldhaus MJ, Siegel RW (2004) Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods 290:69-80
46. Lipovsek D, Pluckthun A (2004) In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 290:51-67
47. Lonberg N, Taylor LD, Harding FA, et al. (1994) Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856-859
48. Morrison SL, Johnson MJ, Herzenberg LA, et al. (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851-6855
49. Carter P, Presta L, Gorman CM, et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289
50. Rowinsky EK (2004) The ErbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 55:433-457
51. Paganelli G (2003) Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 30:773-776
52. Sharkey RM (2006) Radioimmunotherapy against the tumor vasculature: a new target? J Nucl Med 47(7):1070-1074
53. Govindan SV, Goldenberg DM, Hansen HJ, et al. (2000) Advances in the use of monoclonal antibodies in cancer radiotherapy. Pharm Sci Technol Today 3:90-98
54. Graff CP, Wittrup KD (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration and affinity for retention. Cancer Res 63:1288-1296
55. Jain RK (2001) Delivery of molecular medicine to solid tumours: lessons from in vivo imaging of gene expression and function. J Control Release 74(1-3):7-25
56. Boerman OC, van Schaijk FG, Oyen WJG, et al. (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400-411
57. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136
58. Porter RR (1959) The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J 73:119-26
59. Rousseaux J, Rousseaux-Prevost R, Bazin H (1986) Optimal conditions for the preparation of proteolytic fragments from monoclonal IgG of different rat IgG subclasses. Methods Enzymol 121:663-669
60. Bird RE, Hardman KD, Jacobson JW, et al. (1988) Single-chain antigen-binding proteins. Science 242:423-426
61. Maynard J, Georgiou G (2000) Antibody engineering. Annu Rev Biomed Eng 2:339-376
62. Le Gall F, Reusch U, Little M, et al. (2004) Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 17:357-366
63. Holliger P, Prospero T, Winter G (1993) Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444-6448
64. Iliades P, Kortt AA, Hudson PJ (1997) Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett 409:437-441
65. Dolezal O, De Gori R, Walter M, et al. (2003) Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the VL domain of the scFv-0 (VL-VH) molecule is primarily responsible for formation of a tetramer-trimer equilibrium. Protein Eng 16:47-56
66. Weisser NE, Hall JC (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 27:502-520
67. Ward ES, Güssow D, Griffiths AD, et al. (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544-546
68. Stijlemans B, Conrath K, Cortez-Retamozo V, et al. (2004) Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies African try panosomes as paradigm. J Biol Chem 279:1256-1261
69. Lauwereys M, Ghahroudi MA, Desmyter A, et al. (1998) Potent enzyme inhibitors derived from dromedary heavy chain antibodies. EMBO J 17:3512-3520
70. Reichert JM (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9:423-430
71. Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody fragments. Nat Biotechnol 27(4):331-337
72. Ferl GZ, Kenanova V, Wu AM, et al. (2006) A two-tiered physiologically based model for dually labelled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5:1550-1558
73. Lin Y, Pagel J, Axworthy D, et al. (2006) A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 66:3884-3892
74. Cumber AJ, Ward ES, Winter G, et al. (1992) Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J Immunol 149:120-126
75. Shimba N, Torigoe H, Takahashi H, et al. (1995) Comparative thermodynamic analyses of the Fv, Fab and Fab fragments of anti-dansyl mouse monoclonal antibody. FEBS Lett 360:247-250
76. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713
77. Förster GJ, Santos EB, Smith-Jones PM, et al. (2006) Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-Biotin: strategies for reduction of the renal dose. J Nucl Med 47:140-149
78. Goodwin D, Meares C, Diamanti C, et al. (1984) Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur J Nucl Med 9:209-215
79. Goodwin DA, Mears CF, McTigue M, et al. (1986) Monoclonal antibody hapten radiopharmaceutical delivery. Nucl Med Commun 7:569-580
80. 99mTc]PnAO-biotin. Eur J Nucl Med Mol Imaging 21(4):314-321
81. Goodwin DA, Meares CF (2001) Advances in pretargeting biotechnology. Biotechnol Adv 19:435-450
82. Barbet J, Kraeber-BodereF VJP, et al. (1999) Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 14:153-166
83. 90Y radioimmunotherapy in a mouse xenograft model. J Immunother 16:158
84. Moro M, Pelagi M, Fulci G, et al. (1997) Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 57:1922-1928
85. Paganelli G, Pervez S, Siccardi AG, et al. (1990) Intraperitoneal radiolocalization of tumors pretargeted by biotinylated monoclonal antibodies. Int J Cancer 45:1184-1189
86. Yao Z, Zhang M, Kobayashi H, et al. (1995) Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med 36:837-841
87. He J, Liu G, Gupta S, et al. (2004) Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. J Nucl Med 45:1087-1095
88. Bagshawe KD, Sharma SK, Begent RH (2004) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 4:1777-1789
89. Green NM (1990) Avidin and streptavidin. Methods Enzymol 184:51-67
90. Sharkey RM, Karacay H, Griffiths GL, et al. (1997) Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjugate Chem 8:595-604
91. Theodore LJ, Axworthy DB (1997) Cluster clearing agents. PCT Application International Publ. No. W097/46098, International Bureau of WIPO Geneva, Switzerland
92. Le Doussal JM, Martin M, Gautherot E, et al. (1989) In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30:1358-1366
93. Behr TM, Memtsoudis S, Sharkey RM, et al. (1998) Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and antitumor efficacy. Int J Cancer 77:787-795
94. Sharkey RM, Karacay H, Cardillo TM, et al. (2005) Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11:7109s-7121s
95. Karacay H, Sharkey RM, McBride WJ, et al. (2002) Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem 13:1054-1070
96. Weiden PL, Breitz HB, Press O, et al. (2000) Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 15:15-29
97. Peptide therapeutics foundation (2010) Development trends for peptide therapeutics. Report Summary. http://www.peptidetherapeutics.org/PTF-report- summary-2010.pdf.
98. 99mTc-labelled peptide-based radiopharmaceuticals: an overview. Nucl Med Commun 20:1093-1112
99. Jain RK (1987) Transport of molecules in the tumour interstitium: a review. Cancer Res 47:3039-51
100. 99mTc. Q J Nucl Med 40:221-233
101. Okarvi SM (2008) Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer. Cancer Treat Rev 34:13-26
102. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
103. Heppeler A, Froidevaux S, Eberle AN, et al. (2000) Receptor targeting for tumour localisation and therapy with radiopeptides. Curr Med Chem 7:971-994
104. Lewin MJ (1986) Somatostatin receptors. Scand J Gastroenterol Suppl 119:42-46
105. Reubi JC, Laissue J, Krenning E, et al. (1992) Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43:27-35
106. Veber DF, Freidlinger RM, Perlow DS, et al. (1981) A potent cyclic hexapeptide analogue of somatostatin. Nature 292:55-58
107. Ginj M, Chen J, Walter MA, et al. (2005) Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11(3):1136-1145
108. Rosenberg L, Brown RA (1991) Sandostatin in the management of nonendocrine gastrointestinal and pancreatic disorders: a preliminary study. Cancer J Surg 34:223-229
109. Giusti M, Ciccarelli E, Dallabonzana D, et al. (1997) Clinical results of long term slow release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277-284
110. Stiefel F, Morant R (1993) Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer 1:57-58
111. Kwekkeboom DJ, Hoff AM, Lamberts SW, et al. (1992) Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol 128:818-821
112. Kaltsas GA, Papadogias D, Makras P, et al. (2005) Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 12:683-699
113. de Jong M, Bakker WH, Krenning EP, et al. (1997) Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, D-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24(368-3):71
114. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198
115. 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 6:214-220
116. 188Re-lanreotide in athymic mice with induced human cancer tumors. Int J Pharm 310:125-130
117. Lamberts SWJ, van der Lely AJ, de Herder WW, et al. (1996) Drug therapy: octreotide. N Engl J Med 334:246-254
118. Bruns C, Lewis I, Briner U, et al. (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
119. Oberg K (1996) Neuroendocrine gastrointestinal tumours. Ann Oncol 7:453-463
120. Moody TW, Chan D, Fahrenkrug J, et al. (2003) Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 9:495-509
121. Weiner RE, Thakur ML (2005) Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 19(3):145-163
122. Hruby VJ, Sharma SD, Toth K, et al. (1993) Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann NY Acad Sci 680:51-63
123. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 41:429-438
124. Schumacher T, Eichhorn K, Hofer S, et al. (2001) Diffusible brachytherapy (DBT) with radiolabelled substance P in high grade gliomas: first observations [abstract]. Eur J Nucl Med 28:1040
125. Reubi JC (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36:1825-1835
126. Valkema R, De Jong M, Bakker WH, et al. (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32:110-122
127. Otte A, Mueller-Brand J, Dellas S, et al. (1998) Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 351:417-418
128. Emami B, Lyman J, Brown A, et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122
129. 111In-octreotide in mice and rats. J Nucl Med 47:528-533
130. Kassis AI, Adelstein SJ (2005) Radiobiologic principles in radionuclide therapy. J Nucl Med 46(suppl 1):4S-12S
131. O'Donnell RT (2006) Improving systemic targeted radiotherapy. J Nucl Med 47(5):738-739
132. Nunez MI, Villalobos M, Olea N, et al. (1995) Radiation-induced DNA double-strand breaks rejoining in human tumour cells. Br J Cancer 71:311-316
133. Mettler FA, Upton AC (1995) Medical effects of ionizing radiation, 2nd edn. Saunders, Philadelphia
134. National Research Council (1999) Health effects of exposure to radon. National Academy Press, Washington
135. Rutter C, Weissman DE (2004) Radiation for palliation-Part 1. J Palliat Med 7(6):865-867
136. Yao Z, Garmestani K, Wong KJ, et al. (2001) Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 42:1538-1544
137. Zalutsky MR, Vaidyanathan G (2000) Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 6:1433-1455
138. 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells. Radiat Res 155:328-334
139. Qaim SM (2001) Therapeutic radionuclides and nuclear data. Radiochim Acta 89:297-302
140. Adama MJ, Wilbur DS (2005) Radiohalogens for imaging and therapy. Chem Soc Rev 34:153-163
141. Sattelberger AP, Bryan JC (1994) Comprehensive Organometallic Chemistry II. Elsevier, Amsterdam, vol. VI and references cited therein
142. Alberto R (2004) Comprehensive coordination chemistry II. Elsevier: Amsterdam, p. 127, vol. V and references cited therein.
143. Abram U (2004) Comprehensive coordination chemistry II. Elsevier: Amsterdam, p. 271, vol. V and references cited therein.
144. 188Re-pharmaceuticals. Adv Drug Deliv Rev 60:1389-1401
145. Klemm W, Bommer H (1937) Zur Kenntnis der Metalle der seltener Erden. Z Anorg Allg Chem 231:138-171
146. 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograftbearing nude mice. Nucl Med Biol 31:213-223
147. De Jong M, Kwekkeboom D, Valkema R, et al. (2003) Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30:463-469
148. De León-Rodríguez LM, Kovacs Z (2008) The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem 19(2):391-402
149. Deshpande SV, DeNardo SJ, Kukis DL, et al. (1990) Yttrium-90-labeled monoclonal antibody for therapy: labelling by a new macrocyclic bifunctional chelating agent. J Nucl Med 31:473-479
150. Maecke HR, Eisenwiener K, Powell P (2002) Prochelators for the preparation of radiometals labelled molecules having improved biological properties. PCT In. App. WO Patent No. 2002024235
151. Amedio JC, Caravan PD, Jacques V, et al. (2005) Preparation of optically pure and enriched isomers of DOTA-type chelating ligands, and contrast agents. PCT In. App. WO Patent No. 2005001415
152. Walker NI, Harmon BV, Gobe GC, et al. (1988) Patterns of cell death. Methods Achiev Exp Pathol 13:18-54
153. Price DL, Sisodia SS, Borchelt DR (1998) Genetic neurodegenerative diseases: the human illness and transgenic models. Science 282:1079-1083
154. Nanji AA, Hiller-Sturmhöfel S (1997) Apoptosis and Necrosis. Two Types of Cell Death in Alcoholic Liver Diseas 21(4):325-330
155. Merlo LMF, Pepper JW, Reid BJ, et al. (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:925-935
156. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23-28
157. Kessel D (1984) Porphyrin localization: a new modality for detection and therapy of tumors. Biochem Pharmacol 33:1389-1393
158. Gomer C (1989) Photodynamic therapy in the treatment of malignancies. Semin Hematol 26:27-34
159. Chen C, Cohen J, Myers C, et al. (1984) Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett 168:70-74
160. Nelson J, Schmiedl U (1991) Porphyrins as contrast media. Magn Reson Med 22:366-71
161. Ebert E, Hofmann S, Swiderski U (1992) Metallopophyrins: tumor-specific contrast agents? In: Rinck PA, Muller RN (eds) New developments in contrast agent research. European Magnetic Resonance Forum Foundation, Hamburg, pp 127-40
162. Ni Y, Marchal G, Van Damme B, et al. (1992) Magnetic resonance imaging, microangiography and histology in a rat model of primary liver cancer. Invest Radiol 27:689-697
163. Ni Y, Marchal G, Yu J, et al. (1995) Localization of metalloporphyrin induced specific enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic and histologic findings. Acad Radiol 2:687-699
164. Ni Y, Petré C, Miao Y, et al. (1997) Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol 32:770-779
165. Ni Y (2008) Metalloporphyrins and functional analogues as MRI contrast agents. Current Medical Imaging Reviews (CMIR) 4:96-112
166. Ni Y, Bormans G, Chen F, et al. (2005) Necrosis avid contrast agents: functional similarity versus structural diversity (review). Invest Radiol 40(8):526-535
167. Ni Y, Bormans G, Marchal G, Verbruggen A (2003) Tissue infarction and necrosis specific compounds (of hypericin derivatives). PCT/BE2004/000107 Patent application
168. Hamer PW, Mc Geachie JM, Davies MJ, et al. (2002) Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 200:69-79
169. Cresens E, Ni Y, Adriaens P, et al. (2001) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them. International Patent Application PCT/BE01/00192
170. Oberdorster E (2004) Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 112:1058-1062
171. Shaaban M, Maskey RP, Wagner-Dobler I, et al. (2002) Pharacine, a natural p-cyclophane and other indole derivatives from Cytophaga sp. Strain AM13. 1. J Natl Prod 65:1660-1663
172. www.aeschylus-philanthropy.eu/index.php/b/project/oncocidia
173. 123I]iodohypericin μSPECT. Eur Heart J 29(2):260-269
174. Ni Y, Pislaru C, Bosmans H, et al. (2001) Intracoronary delivery of Gd-DTPA and gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol 11:876-883
175. Ginj M, Zhang H, Waser B, et al. (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. PNAS 103(44):16436-16441